1 Diabetes, Obesity and Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.
2 Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health , Bethesda, Maryland.
Thyroid. 2017 Aug;27(8):1017-1024. doi: 10.1089/thy.2016.0668. Epub 2017 Jul 19.
Although a family history of thyroid cancer is one of the main risk factors for thyroid cancer, the benefit of screening individuals with a family history of thyroid cancer is not known.
A prospective cohort study was performed with yearly screening using neck ultrasound and fine-needle aspiration biopsy of thyroid nodule(s) >0.5 cm in at-risk individuals whose relatives were diagnosed with familial non-medullary thyroid cancer (FNMTC). The eligibility criteria were the presence of thyroid cancer in two or more first-degree relatives and being older than seven years of age. Twenty-five kindred were enrolled in the study (12 families with two members affected, and 13 with three or more members affected at enrollment).
Thyroid cancer was detected by screening in 4.6% (2/43) of at-risk individuals from families with two members affected, and in 22.7% (15/66) of at-risk members from families with three or more patients affected (p = 0.01). FNMTC detected by screening was characterized by a smaller tumor size (0.7 ± 0.5 cm vs. 1.5 ± 1.1 cm; p = 0.006), a lower rate of central neck lymph node metastases (17.6% vs. 51.1%; p = 0.02), less extensive surgery (hemithyroidectomy 23.5% vs. 0%; p = 0.002), and a lower rate of radioactive iodine therapy (23.5% vs. 79%; p < 0.001) compared to those affected at enrollment.
Screening of at-risk family members resulted in earlier detection of low-risk FNMTC and was associated with a less aggressive initial treatment. Screening with thyroid ultrasound should be considered in kindred with three or more family members affected by FNMTC. Since active screening might be associated with the risk of overtreatment, it should be implemented with caution, specifically in elderly individuals.
尽管甲状腺癌家族史是甲状腺癌的主要危险因素之一,但目前尚不清楚对有甲状腺癌家族史的个体进行筛查的获益。
对有家族性非髓样甲状腺癌(FNMTC)病史的高危人群进行前瞻性队列研究,每年进行颈部超声和甲状腺结节细针抽吸活检筛查。入选标准为两个或两个以上一级亲属患有甲状腺癌,且年龄大于 7 岁。共纳入 25 个家系(2 个成员患病的家系 12 个,3 个或更多成员患病的家系 13 个)。
在 2 个成员患病的家系中,筛查发现 4.6%(2/43)的高危个体患有甲状腺癌,在 3 个或更多成员患病的家系中,筛查发现 22.7%(15/66)的高危成员患有甲状腺癌(p=0.01)。筛查出的 FNMTC 具有以下特点:肿瘤体积较小(0.7±0.5cm 比 1.5±1.1cm;p=0.006)、中央颈部淋巴结转移率较低(17.6%比 51.1%;p=0.02)、手术范围较小(甲状腺半切除术 23.5%比 0%;p=0.002)、放射性碘治疗率较低(23.5%比 79%;p<0.001)。
对高危家族成员进行筛查可更早发现低危 FNMTC,并与更具侵袭性的初始治疗相关。对有 3 个或更多 FNMTC 家族成员患病的家系进行甲状腺超声筛查是合理的。由于主动筛查可能与过度治疗的风险相关,因此应谨慎实施,特别是在老年人群中。